← Back to Search

Brachytherapy

Brachytherapy for Prostate Cancer

Phase 1 & 2
Waitlist Available
Research Sponsored by Center for Molecular Medicine
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age: 21 and over
Histologically proven locally recurrent prostate cancer that has failed conventional therapy (i.e., external beam radiotherapy, radioactive seed implants, and hormonal therapy)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial is studying how well brachytherapy works in treating patients with prostate cancer that has returned after previous treatment.

Who is the study for?
This trial is for men over 21 with recurrent prostate cancer that hasn't improved after standard treatments like external radiation or hormone therapy. They should have a PSA increase, a prostate size between 2-5 cm preferred, and no signs of cancer spread. Participants need normal blood counts and kidney function, with no past damage to the urinary or digestive systems.Check my eligibility
What is being tested?
The study is examining brachytherapy's effectiveness in treating recurrent prostate cancer. Brachytherapy involves placing radioactive material directly into or near the tumor to target and kill cancer cells more effectively than traditional methods.See study design
What are the potential side effects?
Brachytherapy may cause side effects such as discomfort at the implant site, urinary issues like frequency or urgency, bowel changes including rectal bleeding or diarrhea, erectile dysfunction, and fatigue.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 21 years old or older.
Select...
My prostate cancer came back after treatments like radiation or hormone therapy.
Select...
I have never had an injury to my urethra, bladder, or rectum.
Select...
My hemoglobin level is at least 9 g/dL, transfusions included.
Select...
My cancer has not spread to other parts of my body.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

Center for Molecular MedicineLead Sponsor
5 Previous Clinical Trials
213 Total Patients Enrolled
Wayne S. Court, MD, PhDStudy ChairCenter for Molecular Medicine
1 Previous Clinical Trials

Media Library

Brachytherapy (Brachytherapy) Clinical Trial Eligibility Overview. Trial Name: NCT00005939 — Phase 1 & 2
Prostate Cancer Research Study Groups:
Prostate Cancer Clinical Trial 2023: Brachytherapy Highlights & Side Effects. Trial Name: NCT00005939 — Phase 1 & 2
Brachytherapy (Brachytherapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00005939 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are recruitment efforts currently ongoing for this medical experiment?

"The clinical trial, which was first published in November 1999 and modified for the last time on the 5th of that same month, is not presently enrolling patients. However, there are over 1300 medical studies actively recruiting individuals at this moment."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Brachytherapy in Treating Patients With Recurrent Prostate Cancer
1999. "Brachytherapy in Treating Patients With Recurrent Prostate Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00005939.
All > Prostate > Recurrent Prostate Cancer
~14 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top